ESR1 and breast cancer: Detecting these patients early could open up additional treatment options that have shown efficacy in the metastatic setting, such as selective estrogen receptor degraders (SERDs) in ESR1‐mutated tumors, or TKIs such as neratinib in ERBB2‐mutated BC.